Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ord Shs (OP:TKPHF)

35.73 -0.62 (-1.71%)
Streaming Delayed Price Updated: 11:36 AM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ord Shs

< Previous 1 2 Next >
News headline image
Current Analysis: Takeda Pharmaceutical ↗
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. Over the past year, Takeda’s share price fell 20.5% from $34.04 to $27.05 as of... 
Via Talk Markets
News headline image
Current Analysis: Takeda Pharmaceuticals (TKPHF) ↗
TKPHF is the largest Japanese drug company. Furthermore the estimated $45.50 dividend income from $1k invested is about 1.64 times greater than Friday’s price of a single share 
Via Talk Markets
News headline image
Takeda Moves Out From Licensing Agreement With Theravance Biopharma ↗
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'... 
Via Benzinga
News headline image
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues ↗
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its  
Via Benzinga
News headline image
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review ↗
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003. 
Via Benzinga
News headline image
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B ↗
 
Via Benzinga
News headline image
Takeda's Dengue Vaccine Candidate Under FDA Priority Review ↗
 
Via Benzinga
News headline image
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook ↗
 
Via Benzinga
News headline image
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids ↗
 
Via Benzinga
News headline image
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says ↗
 
Via Benzinga
News headline image
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients ↗
 
Via Benzinga
News headline image
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged ↗
 
Via Benzinga
News headline image
Why Shares of Phathom Pharmaceutical Jumped This Week ↗
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy. 
Via The Motley Fool
News headline image
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study ↗
 
Via Benzinga
News headline image
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
News headline image
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder ↗
 
Via Benzinga
News headline image
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22 ↗
 
Via Benzinga
News headline image
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings ↗
 
Via Benzinga
News headline image
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report ↗
 
Via Benzinga
News headline image
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets ↗
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome... 
Via Benzinga
News headline image
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. 
Via Benzinga
News headline image
FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder ↗
The  
Via Benzinga
News headline image
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients ↗
 
Via Benzinga
News headline image
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection ↗
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID... 
Via Benzinga
News headline image
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit ↗
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
Via Benzinga
News headline image
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four... 
Via Benzinga
News headline image
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of... 
Via Benzinga
News headline image
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral... 
Via Benzinga
News headline image
Novavax Files For Approval Of Its COVID-19 Vaccine In Japan ↗
Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.